T1	Condition 77 80	CLL
T2	Condition 81 84	SLL
*	OR T2 T1 T3
T3	Condition 88 115	B-cell Non-Hodgkin lymphoma
T4	Condition 117 122	DLBCL
T5	Condition 124 126	FL
T6	Condition 128 131	MCL
T7	Condition 133 136	MZL
T8	Condition 138 164	lymphoplasmacytic lymphoma
T9	Scope 117 164	DLBCL, FL, MCL, MZL, lymphoplasmacytic lymphoma
T10	Scope 77 115	CLL/SLL or B-cell Non-Hodgkin lymphoma
R1	Subsumes Arg1:T10 Arg2:T9	
T11	Value 25 39	at least 18yrs
T12	Person 43 46	age
R2	Has_value Arg1:T12 Arg2:T11	
T13	Procedure 52 66	histologically
T14	Value 67 76	confirmed
R3	Has_value Arg1:T13 Arg2:T14	
R4	AND Arg1:T10 Arg2:T13	
T15	Parsing_Error 168 186	Phase 2a Inclusion
T16	Procedure 188 200	Histological
T17	Condition 211 213	FL
T18	Measurement 214 219	Grade
T19	Value 220 224	1-3A
R5	Has_value Arg1:T18 Arg2:T19	
R6	AND Arg1:T17 Arg2:T18	
T20	Condition 225 229	iNHL
*	OR T20 T17
T21	Condition 248 266	refractory disease
T22	Condition 236 244;259 266	relapsed disease
*	OR T21 T22
T23	Condition 268 272	iNHL
T24	Condition 282 285	LPL
T25	Condition 286 288	WM
T26	Condition 290 293	MZL
*	OR T26 T25 T24
T27	Scope 282 293	LPL/WM, MZL
R7	Subsumes Arg1:T23 Arg2:T27	
T28	Scope 236 266	relapsed or refractory disease
R8	Subsumes Arg1:T28 Arg2:T23	
T29	Condition 296 300	aNHL
T30	Condition 313 318	DLBCL
T31	Condition 320 322	FL
T32	Measurement 323 328	Grade
T33	Value 329 331	3B
R9	Has_value Arg1:T32 Arg2:T33	
T34	Condition 333 336	MCL
T35	Condition 342 357	transformed NHL
T36	Condition 363 379	relapsed disease
T37	Condition 381 384	CLL
T38	Condition 385 388	SLL
T39	Condition 390 394	PTCL
T40	Condition 399 403	CTCL
T41	Condition 410 412	MF
T42	Condition 413 415	SS
*	OR T41 T42
T43	Scope 410 415	MF/SS
R10	Has_scope Arg1:T40 Arg2:T43	
R11	AND Arg1:T35 Arg2:T36	
*	OR T34 T35 T32 T31 T30
T44	Scope 313 379	DLBCL, FL Grade 3B, MCL, and transformed NHL with relapsed disease
R12	Subsumes Arg1:T29 Arg2:T44	
*	OR T29 T23 T37 T38 T39 T40
T45	Drug 467 482	BCL2 inhibitors
T46	Drug 456 459;472 482	BCR inhibitors
*	OR T46 T45
T47	Condition 488 498	intolerant
T48	Scope 456 482	BCR and/or BCL2 inhibitors
R13	Has_scope Arg1:T47 Arg2:T48	
T49	Condition 506 514	relapsed
T50	Condition 515 533	refractory disease
*	OR T49 T50
T51	Temporal 534 544	afterwards
T52	Scope 506 533	relapsed/refractory disease
R14	Has_temporal Arg1:T52 Arg2:T51	
*	OR T52 T47
T53	Temporal 547 552	Prior
T54	Procedure 553 562	treatment
*	OR T54 T53
T55	Condition 567 586	lymphoid malignancy
T56	Condition 604 622	refractory disease
T57	Condition 591 602;615 622	progressive disease
*	OR T56 T57
T58	Drug 662 680	antibody conjugate
T59	Procedure 682 704	cytotoxic chemotherapy
T60	Drug 709 712	TKI
*	OR T60 T59 T58
T61	Multiplier 624 641	≥ 1 prior regimen
T62	Multiplier 643 655	min 2 cycles
T63	Scope 662 712	antibody conjugate, cytotoxic chemotherapy, or TKI
R15	Has_multiplier Arg1:T63 Arg2:T61	
R16	Has_multiplier Arg1:T61 Arg2:T62	
T64	Condition 739 758	Measureable disease
T65	Multiplier 771 781	≥ 1 lesion
T66	Measurement 782 807	≥ 1.5 cm single dimension
T67	Value 782 790	≥ 1.5 cm
R17	Has_value Arg1:T66 Arg2:T67	
T68	Procedure 812 814	CT
T69	Procedure 816 822	CT/PET
T70	Condition 837 849	mass lesions
T71	Condition 828 833;842 849	nodal lesions
*	OR T70 T71
*	OR T69 T68
T72	Condition 864 887	circulating tumor cells
T73	Condition 896 927	Waldenström's macroglobulinemia
T74	Measurement 940 945	IgM l
T75	Value 946 954	> 2X ULN
R18	Has_value Arg1:T74 Arg2:T75	
T76	Condition 960 964	CTCL
T77	Measurement 966 971	mSWAT
T78	Value 972 975	> 0
R19	Has_value Arg1:T77 Arg2:T78	
R20	AND Arg1:T76 Arg2:T77	
A1	Optional T76
A2	Optional T73
R21	AND Arg1:T73 Arg2:T74	
*	OR T76 T73 T72
T79	Scope 828 849	nodal or mass lesions
T80	Scope 812 822	CT, CT/PET
R22	Has_scope Arg1:T66 Arg2:T80	
R23	Has_scope Arg1:T80 Arg2:T79	
T81	Scope 771 975	≥ 1 lesion ≥ 1.5 cm single dimension via CT, CT/PET with nodal or mass lesions; Quantifiable circulating tumor cells; or for Waldenström's macroglobulinemia presence of IgM l > 2X ULN; For CTCL: mSWAT > 0
R24	Subsumes Arg1:T64 Arg2:T81	
T82	Non-query-able 977 1014	Ability to provide diagnostic reports
T83	Parsing_Error 1016 1033	General Inclusion
T84	Measurement 1035 1045	ECOG Score
T85	Value 1049 1055	0 or 1
R25	Has_value Arg1:T84 Arg2:T85	
T86	Measurement 1058 1073	Hematologic ANC
T87	Value 1074 1083	> 1000/uL
R26	Has_value Arg1:T86 Arg2:T87	
T88	Measurement 1088 1096	platelet
T89	Value 1097 1108	> 75,000/uL
R27	Has_value Arg1:T88 Arg2:T89	
T90	Measurement 1111 1127	Serum creatinine
T91	Value 1131 1140	< 1.5 ULN
R28	Has_value Arg1:T90 Arg2:T91	
T92	Measurement 1144 1159	calculated CrCl
T93	Value 1163 1174	> 50 mL/min
R29	Has_value Arg1:T92 Arg2:T93	
*	OR T90 T92
T94	Measurement 1176 1185	Bilirubin
T95	Value 1186 1197	< 20.0mg/dL
T96	Condition 1202 1210	Gilberts
A3	Optional T96
T97	Value 1216 1227	< 2.5 mg/dL
*	OR T95 T96
R30	Has_value Arg1:T96 Arg2:T97	
T98	Scope 1186 1228	< 20.0mg/dL (if Gilberts then < 2.5 mg/dL)
R31	Has_scope Arg1:T94 Arg2:T98	
T99	Measurement 1233 1240	AST/AST
T100	Value 1241 1250	< 2.5 ULN
R32	Has_value Arg1:T99 Arg2:T100	
